Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response
Author Information
Author(s): Richard K. Burt, Tobias Alexander
Primary Institution: Northwestern University
Conclusion
The study suggests that hematopoietic stem cell transplantation (HSCT) is generally ineffective for patients with progressive multiple sclerosis (PMS) without active inflammation, but may benefit certain subsets like active SPMS and those with progression independent of relapse activity (PIRA).
Supporting Evidence
- HSCT has shown better outcomes in relapsing-remitting MS compared to progressive MS.
- Active SPMS patients may still benefit from HSCT due to ongoing inflammation.
- Patients with non-active SPMS did not show improvement after HSCT.
Takeaway
This study shows that stem cell treatment might not help most people with a type of multiple sclerosis that doesn't have much inflammation, but it could help some specific groups.
Methodology
The authors conducted a systematic literature review of publications on HSCT for PMS.
Limitations
The study lacks data on the influence of active neuronal inflammation at baseline on the results.
Participant Demographics
The study included 665 patients with progressive multiple sclerosis, with 74 having primary progressive MS and 591 having secondary progressive MS.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website